Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable objective responses in patients with HER2-positive breast cancer who were heavily pretreated. Although T-DXd had a generally manageable safety profile, interstitial lung disease (ILD) was identified as a risk warranting proactive awareness and management.
Despite the fact that HER2-directed therapies like trastuzumab, pertuzumab, and T-DM1 have led to improved outcomes for patients with HER2-positive advanced breast cancer, resistance to these drugs is almost inevitable. Once patients develop resistance, it is not clear what treatment should be given, highlighting the unmet medical need for new and improved therapies for these patients. T-DXd is an antibody-drug conjugate with an HER2 antibody, peptide-based cleavable linker, and a novel to...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Partial breast irradiation could be as effective as whole breast irradiation Next Article
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement »